PTGER3 and type 2 diabetes mellitus: Combined with a significant upregulation of islet Ptger3 expression and the impact of an EP3-selective agonist on GSIS, our results link full-body metabolic derangements specifically with the EP3-mediated β-cell dysfunction of T2D.